| アブストラクト | This retrospective cohort study on adults undergoing colectomy from 2010 to 2019 used linked primary (Clinical Practice Research Datalink), and secondary (Hospital Episode Statistics) care data to determine the prevalence of persistent postoperative opioid use following colectomy, stratified by pre-admission opioid exposure, and identify associated predictors. Based on pre-admission opioid exposure, patients were categorised as opioid-naive, currently exposed (opioid prescription 0-6 months before admission) and previously exposed (opioid prescription within 7-12 months before admission). Persistent postoperative opioid use was defined as requiring an opioid prescription within 90 days of discharge, along with one or more opioid prescriptions 91-180 days after hospital discharge. Multivariable logistic regression analyses were conducted to obtain odds ratios for predictors of persistent postoperative opioid use. Among the 93,262 patients, 15,081 (16.2%) were issued at least one opioid prescription within 90 days of discharge. Of these, 6791 (45.0%) were opioid-naive, 7528 (49.9%) were currently exposed and 762 (5.0%) were previously exposed. From the whole cohort, 7540 (8.1%) developed persistent postoperative opioid use. Patients with pre-operative opioid exposure had the highest persistent use: 5317 (40.4%) from the currently exposed group; 305 (9.8%) from the previously exposed group; and 1918 (2.5%) from the opioid-naive group. The odds of developing persistent opioid use were higher among individuals who used long-acting opioid formulations in the 180 days before colectomy than those who used short-acting formulations (odds ratio 3.41 (95%CI 3.07-3.77)). Predictors of persistent opioid use included: previous opioid exposure; high deprivation index; multiple comorbidities; use of long-acting opioids; white race; and open surgery. Minimally invasive surgical approaches were associated with lower odds of persistent opioid use and may represent a modifiable risk factor. |
|---|
| ジャーナル名 | Anaesthesia |
|---|
| 投稿日 | 2023/6/2 |
|---|
| 投稿者 | Baamer, R M; Humes, D J; Toh, L S; Knaggs, R D; Lobo, D N |
|---|
| 組織名 | Division of Pharmacy Practice and Policy, School of Pharmacy, University of;Nottingham, Nottingham, UK.;Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University,;Jeddah, Saudi Arabia.;Nottingham Digestive Diseases Centre and National Institute for Health Research;Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust;and University of Nottingham, Queen's Medical Centre, Nottingham, UK.;Pain Centre Versus Arthritis, University of Nottingham, Nottingham, UK.;David Greenfield Metabolic Physiology Unit, MRC Versus Arthritis Centre for;Musculoskeletal Ageing Research, School of Life Sciences, University of;Nottingham, Queen's Medical Centre, Nottingham, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37265223/ |
|---|
